This role of CBP and p300 as tumor suppressors has been also observed in B-NHL, where its inactivating mutation is a common event in FL and DLBCL, providing a rationale for employing drugs with the capacity to modulate acetylation and deacetylation processes in these tumors (Cerchietti et al., 2010; Mullighan et al., 2011; Pasqualucci et al., 2011a). Here, EP300 is linked to neoplasm.